Patient-specific lymphoma idiotype antigen (Id)

The patient-specific lymphoma idiotype antigen refers to the unique set of antigenic determinants located within the variable regions of the immunoglobulin molecule expressed on the surface of malignant B-cells. In B-cell lymphomas, such as follicular lymphoma, the tumor arises from a single clone, meaning every cancer cell displays the same unique B-cell receptor (BCR) idiotype, which acts as a true tumor-specific neoantigen (Levy et al., 2011, Curr Top Microbiol Immunol). Because this idiotype is not found on normal B-cells or other healthy tissues, it serves as a highly specific target for personalized immunotherapy. Therapeutic approaches involve the production of patient-specific vaccines, where the idiotype protein is purified or recombinantly produced and then used to prime the patient's immune system to recognize and eliminate the lymphoma cells (Schuster et al., 2011, J Clin Oncol). Despite the high specificity, the clinical success of idiotype vaccines has been mixed, often requiring combination with potent adjuvants or use in the minimal residual disease setting to overcome immunosuppressive tumor environments and the inherent low immunogenicity of self-derived proteins.

Other names

Tumor-specific idiotypeB-cell receptor idiotypeLymphoma idiotypeId antigenClonal immunoglobulin idiotype

Active immunotherapy involving the administration of patient-specific idiotype proteins, often conjugated to carrier proteins like Keyhole Limpet Hemocyanin (KLH) and administered with adjuvants like GM-CSF, to induce a specific T-cell and B-cell mediated immune response against the malignant B-cell clone (Schuster et al., 2011, J Clin Oncol).